Skip to main navigation Skip to search Skip to main content

Doripenem: A new addition to the carbapanem class of antimicrobials

  • Jason J. Schafer
  • , Debra A. Goff
  • , Julie E. Mangino

Research output: Contribution to journalReview articlepeer-review

Abstract

Doripenem (DPM) is the newest antimicrobial in the carbapenem class. It is a broad spectrum agent with activity against gram-positive, gram-negative and anaerobic bacteria. in vitro Susceptibility testing has demonstrated potent activity for many drug resistant gram-negative pathogens including some that are resistant to imipenem and meropenem. It appears to be less likely to induce resistance for certain pathogens compared to the other carbapenems. The purpose of this review is to introduce DPM and describe its potential role in managing infections due to multi-drug resistant gram-negative bacteria. This article also reviews recent patents related to the carbapenem class of antimicrobials.

Original languageEnglish
Pages (from-to)18-28
Number of pages11
JournalRecent Patents on Anti-Infective Drug Discovery
Volume4
Issue number1
DOIs
StatePublished - 2009

Keywords

  • Carbapenem
  • Doripenem
  • Multi-drug resistant
  • Pharmacodynamics
  • Pseudomonas

Fingerprint

Dive into the research topics of 'Doripenem: A new addition to the carbapanem class of antimicrobials'. Together they form a unique fingerprint.

Cite this